Psychedelic highlights | August 31 – 04

Shares :

5
(2)

Here is a summary of the news from the last week in the psychedelics market. The value of the psychedelics market is more than $100 billion according to Cannacord most recent report.


M2Bio Sciences, Inc | WUHN on OTC

M2Bio Sciences | WUHN in collaboration with researchers from the University of Pretoria published the first study of several to come:

Study : Phytochemical, Cytotoxicity, Antioxidant and Anti-Inflammatory Effects of Psilocybe Natalensis Magic Mushroom.

This is another important step for M2Bio Sciences | WUHN who is very close to put on the market a series of products based on CBD and Mushroom.

M2Bio Sciences Inc | WUHN  has 48 Millions shares on the market, therefore 27 Millions restricted and 14 Millions held in DTC which leaves a float of approximately 7 Millions shares. (According to OTC website)

Visit M2Bio Sciences profile| HERE


Revive Therapeutics | RVV RVVTF

On September 02, Revive Therapeutics | RVV RVVTF enters into Clinical Trial Agreement to Evaluate Psilocybin for the Treatment of Methamphetamine Use Disorder

Revive Therapeutics has entered into a Clinical Trial Agreement (CTA), dated August 28, 2020, with the Board of Regents of the University of Wisconsin System (UWS) to conduct a clinical study entitled, “Phase I Study of the Safety and Feasibility of Psilocybin in Adults with Methamphetamine Use Disorder.

“We are delighted to be collaborating with clinical researchers at the University of Wisconsin‒Madison to advance development of psilocybin for the potential treatment of methamphetamine use disorder,”

-said Michael Frank, Revive’s Chief Executive Officer.

“We are building a pipeline of clinical-stage psychedelic-derived therapies for addiction disorders with a focus on psilocybin with unique dosage forms.”

We must not forget that Revive Therapeutics just announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Visit Revive Therapeutics profile | HERE

Covid phase 2/3 company valuation


Red Light Holland | TRIP

On September 02, Red Light Holland Announces Arrangement to Launch Sale of Psychedelic Truffle Microdosing Packs in the Netherlands

“All of us at Red Light Holland are very excited as our Microdosing Packs are so close to being on shelves and available for online purchases. We are still anticipating our premiere product launch, with our newly coined phrase “iMicrodose,” happening later this month, and working so closely with McSmart is something we are truly appreciative of,”

-said Todd Shapiro, Chief Executive Officer and Director of the Company

Visit Red Light Holland website | HERE


For more information on the psychedelics market and all the companies involved | HERE

Sign up for MORE news updates !


This article is written and published by The Cannabis Stock


Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Disclosure : Wuhan General group inc and Revive Therapeutics are clients of The Cannabis Stock.

Click on a star to rate this article !

Average rating 5 / 5. Vote count: 2

No votes so far! Be the first to rate this post.


Shares :